REDEYE
Impala Nordic
OncoZenge is a Swedish pharmaceutical company developing innovative treatments in pain management, with a focus on patients suffering from oral mucositis – a painful side effect of cancer treatment. The company’s lead product candidate, BupiZenge®, is based on a well-known substance in a new formulation and aims to meet a large medical need. OncoZenge is a spin-off from Moberg Pharma and is headquartered in Stockholm.